In this episode of M&A Talks Europe, we dive into the high-stakes battle between private equity giants for Sanofi’s consumer medicine division, Opella, ultimately won by American CD&R for €15.5 billion. We’ll explore how this deal fits into broader trends in both the pharmaceutical and private equity sectors, Sanofi’s shift to biopharma, and the political uproar in France over healthcare sovereignty because of sale of Doliprane, most popular medicine in France. Tune in to learn more about pharma and carve-out deals!